S.T.O.P. HIV Now: Screen.Treat. Prevent. Overcome.

Activity Details
  • Credit Type: Other
  • Credit Amount: 0.50
  • Cost: Free
  • Release: Mar 26, 2020
  • Expires: Nov 30, 2021
  • Estimated Time to Complete:
    30 Minutes
  • Average User Rating:
    ( Ratings)

Faculty

Keisa Fallin-Bennett Keisa Fallin-Bennett, MD, MPH
Associate Professor
Family and Community Medicine
University of Kentucky College of Medicine
Lexington, Kentucky

David Griffith David Griffith, MD
Clinical Associate
Division of Infectious Disease
Johns Hopkins School of Medicine
Baltimore, Maryland

Needs Statement

Individuals living with an unknown HIV infection account for approximately 40% of new HIV infections, due to a lack of screening (Webel AR, Longenecker CT, Gripshover B, et al., 2014). The CDC estimates that more than 50% of American adults of all ages have never been tested for HIV. Similar screening rates have been found for specific patient populations, such as men who have sex with men (MSM) and people who inject drugs (PWID), who have a higher risk of HIV infection. Effective HIV screening remains the most significant barrier to prevention and treatment. Therefore, there is a need for providers to place a greater emphasis to screen all patients over the age of 13 in an effort to prevent more new diagnoses and reduce transmission rates.

Target Audience

This activity is intended for certified state technicians (CSTs). 

Objectives

1. Explain the benefits of screening people for HIV infection.
2. Describe risk factors that give people higher chances of becoming infected with HIV.

Accreditation

Other
UK Healthcare CECentral certifies this activity for 0.50 hours of participation.

Faculty Disclosure

No speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

The program is jointly provided by the University of Kentucky and DKBmed in collaboration with Postgraduate Institute for Medicine and is supported by an independent medical education grant from Gilead Sciences, Inc.